[Ip-health] Join DNDi for launch of Global Antibiotic Research and Development (GARD) Partnership

James Arkinstall jarkinstall at dndi.org
Mon May 23 06:28:53 PDT 2016


Those attending the World Health Assembly may be interested in attending the launch of the Global Antibiotic Research and Development (GARD) Partnership tomorrow Tuesday.
RSVP glandry at dndi.org<mailto:glandry at dndi.org> or contacts below



WHAT

The mission of the Global Antibiotic Research and Development (GARD) Partnership is to develop new antibiotic treatments addressing antimicrobial resistance and to promote their responsible use for optimal conservation, while ensuring equitable access for all in need. GARD is being incubated by the Drugs for Neglected Diseases initiative (DNDi) in collaboration with the World Health Organization (WHO) and in support of the Global Action Plan for Antimicrobial Resistance.



A partnership model for product development based on the experience gained from the field of neglected diseases can provide an important element of the overall strategy for R&D in the field of antibiotics. Such a partnership can test new incentives that also contribute to conservation of and access to new antibiotic treatments. By doing so, it can provide an important alternative to the traditional market-driven pharmaceutical approach, by focusing on products that the pharmaceutical industry will likely not develop for lack of profitability.



More info here: dndi.org/GARD



WHEN

Tuesday 24th May 18.30-20.30



WHERE

Chateau des Penthes, 18 Chemin de l'Imperatrice, Pregny-Chambesy

RSVP glandry at dndi.org<mailto:glandry at dndi.org> or contacts below

James Arkinstall | Head of Communications and Advocacy
Drugs for Neglected Diseases initiative
15 Chemin Louis-Dunant | 1202 Geneva | Switzerland
Tel: +41 22 9077 885 | Mob: +41 79 3929 823  jarkinstall at dndi.org<mailto:jarkinstall at dndi.org> | skype: dndi-james-arkinstall
Best Science for the Most Neglected | www.dndi.org<http://www.dndi.org/>




More information about the Ip-health mailing list